[Megathread] THE ULTIMATE BONE GUIDE - every compound, every mechanism, every cope destroyed (No medical advice)
firstly I’m differentiating between 4 categories because most of you mix them up constantly and its painful to see:
- BONE LENGTH = longitudinal growth via epiphyseal plates
- BONE MASS = total amount of bone tissue you have
- BONE DENSITY = mineral content per unit volume (what a DEXA scan measures)
- BONE DIMORPHISM = sexually dimorphic shape - wider jaw, brow ridge, broader frame - driven by periosteal apposition
these are NOT the same thing. a compound can max out one category and do literally nothing for another. if you dont understand this distinction the rest of the thread is useless to you.
1. HGH / GH-IGF-1 AXIS
the most overhyped compound in this community for bone purposes.
GH works through IGF-1 on growth plate chondrocytes. its the primary driver of longitudinal bone growth - this is not debatable, its established endocrinology. GH-deficient mice have 10-15% less pubertal bone expansion than wild type. in children with GH deficiency, recombinant HGH is the standard treatment and it works.
BUT - and this is where most of you are coping - GH/IGF-1 does NOT create sexual dimorphism. callewaert et al (JBMR 2010) showed that IGF-1 knockout mice have literally zero skeletal sexual dimorphism. the bones are smaller but equally shaped between sexes. GH makes bones bigger in all directions. it does not make them more male. these are completely different processes mediated by completely different receptors.
for length its probably the best single compound if your plates are open. for mass and density its moderate at best. for dimorphism its basically irrelevant.
length: very strong. mass: decent. density: mediocre. dimorphism: basically nothing.
requirement: open growth plates for any length effect. adults only get mild mass/density benefits and even those are debatable at non-supraphysiological doses.
(Callewaert et al 2010; Venken et al JBMR 2005; Vanderschueren Endocr Rev 2004)
2. ANDROGENS (Testosterone, DHT, Trenbolone)
this is where dimorphism actually is superior. if you care about sexually dimorphic bone structure - wider mandible, more prominent brow, thicker zygomatic arches, broader clavicles - androgens via the androgen receptor are the primary and arguably only proven mechanism.
the pathway: AR activation on periosteal osteoblasts -> new bone laid on the OUTER surface of existing bone -> increased cortical thickness, greater cross-sectional area, more bending resistance. vandenput and ohlsson (PMC3955330, 2014) confirmed that androgens promote trabecular bone thickness in young adulthood and cortical consolidation through periosteal apposition in midlife and beyond. male periosteal bone formation runs about 70% higher than female during puberty. this is what makes male skulls and frames look male.
now the potency ranking for dimorphism specifically:
halotestin (fluoxymesterone) - 19x AR potency vs testosterone. does not aromatize (c11b hydroxyl blocks aromatase). no progestogenic activity. uniquely inhibits 11b-HSD2 which blocks cortisol inactivation in bone tissue (odermatt et al toxicol sci 2012, PMID 22273746). estimated dimorphic remodeling potency roughly 8-10x testosterone.
trenbolone - 3-5x AR potency vs testosterone. does not aromatize. BUT it IS progestogenic which suppresses endogenous testosterone and estrogen production over time. you actually need some estrogen for bone mineralization so tren can impair this long term. estimated roughly 3-4x testosterone for dimorphism.
DHT - about 3x AR potency vs testosterone. does not aromatize. however it gets metabolized by 3a-HSD in bone tissue which reduces local potency. roughly 3x testosterone in theory but probably less in practice.
testosterone - the baseline at 1x. aromatizes to estrogen which simultaneously helps density but also narrows the medullary cavity via endosteal apposition. mixed bag for pure dimorphism.
nandrolone - 1-2x AR, slightly aromatizes, progestogenic. roughly similar to test, maybe slightly worse for dimorphism because of the progesterone activity.
androgens overall: moderate for length (only during puberty), decent for mass, decent for density, unmatched for dimorphism.
(Saartok et al J Steroid Biochem 1984; Vandenput & Ohlsson PMC3955330 2014; Vanderschueren JCEM 2006)
3. FGFR3 INHIBITORS / CNP ANALOGS (Vosoritide, Infigratinib, TYRA-300)
FGFR3 is a receptor that when overactivated acts as a BRAKE on endochondral bone growth. its gain-of-function mutations cause achondroplasia (dwarfism). these drugs release that brake.
vosoritide is a CNP analog - it binds NPR-B receptor which inhibits the MAPK pathway downstream of FGFR3. infigratinib and TYRA-300 are direct FGFR3 tyrosine kinase inhibitors that block the receptor itself.
the clinical data: vosoritide phase 3 RCT showed +1.57 cm/year growth velocity vs placebo in achondroplasia kids aged 5-12 (savarirayan et al, lancet). meta-analysis across 696 patients showed +1.82 cm/year. in mouse models TYRA-300 normalized long bone length by 25-26% toward wild type. infigratinib at higher doses showed more bone growth than vosoritide in the same mouse model (JCI insight 2025).
now the critical part most of you will ignore: these were developed for people with pathologically overactive FGFR3. in a normal person FGFR3 is already functioning at baseline levels. inhibiting it in someone without the mutation could cause unpredictable cartilage and bone overgrowth. this is NOT a height supplement for healthy people. we have essentially zero data on what FGFR3 inhibition does to normal human growth plates.
pure length compound. zero effect on mass, density, or dimorphism. requires open growth plates. designed for a specific genetic disease.
(Savarirayan et al Lancet 2020; JCI Insight 2025; BioMarin clinical data)
4. PTH ANALOGS (Teriparatide / Forteo, Abaloparatide / Tymlos)
intermittent PTH pulses directly stimulate osteoblasts. teriparatide is recombinant PTH(1-34). abaloparatide is a PTHrP analog that supposedly causes less bone resorption. both increase bone formation rate on all surfaces - trabecular and cortical.
the data: teriparatide gives you about +20% trabecular vertebral vBMD at 12 months. cortical thickness increased about 4.3% at lumbar vertebrae. P1NP (formation marker) goes through the roof. these are real numbers from real trials.
the catch: PTH also increases bone resorption. its pro-remodeling meaning it speeds up both formation AND breakdown. the net gain is positive but its not as clean as romosozumab which actually suppresses resorption at the same time.
for length: nothing. for mass and density: strong, probably the second best option after romosozumab. for dimorphism: weak because it acts on all bone surfaces equally - endosteal, periosteal, trabecular. it doesnt preferentially drive periosteal apposition in a sexually dimorphic pattern.
(Neer et al NEJM 2001; multiple phase 3 trials)
5. AROMATASE INHIBITORS (Letrozole, Anastrozole, Exemestane)
this is the one that gets the most hype in these communities and also the most misunderstood.
the mechanism is simple: estrogen is the primary signal for growth plate closure. block estrogen production -> plates stay open longer -> more years of longitudinal growth -> taller adult height. men with aromatase gene mutations were still growing past age 24 with unfused plates and ended up over 190cm. the biology is clear.
letrozole is more potent than anastrozole - 88% vs 85% tissue aromatase blockade with residual estradiol at 5.9% vs 10.1% respectively.
the data: wickman et al (lancet 2001) RCT in boys with constitutional delay of puberty - letrozole + testosterone group saw predicted adult height increase of 5.1 cm (p=0.004) vs testosterone + placebo. bone age advanced only 0.9 years in 18 months with letrozole vs 1.7 years with placebo. thats a massive slowdown in skeletal maturation.
hero et al 2006 confirmed near-final height increase with letrozole during adolescence. final height for letrozole group was 171 cm vs 168.8 cm for controls (p=0.04) in one smaller study.
BUT - and this is a big but - varimo et al (frontiers 2019) showed that letrozole given to PRE-pubertal or EARLY pubertal boys did NOT increase adult height at all. 164.8 cm letrozole vs 163.7 cm placebo, not significant. timing matters enormously. it seems to work best during mid to late puberty when growth plates are actively being pushed toward closure by rising estrogen.
the downsides nobody wants to talk about: AIs dont make bones grow faster. they just keep plates open. you also lose estrogen-mediated bone density benefits. some studies found vertebral deformities in AI-treated boys. bone density at the lumbar spine was lower in letrozole-treated boys. estrogen is genuinely important for bone health in males and nuking it has consequences.
for length: strong but only indirectly and only with correct timing during puberty. for mass: bad, probably net negative. for density: actively harmful - estrogen is essential for density. for dimorphism: mild indirect benefit because you get more time with androgens acting on periosteal bone without estrogenic epiphyseal closure, but you also lose estrogen-mediated endosteal apposition.
(Wickman et al Lancet 2001; Hero et al Clin Endocrinol 2006; Varimo et al Front Endocrinol 2019)
6. ROMOSOZUMAB (Evenity - Anti-Sclerostin Antibody)
this is the actual king of bone mass and density and it isnt close.
sclerostin is a protein produced by osteocytes that inhibits the Wnt/b-catenin pathway, which is basically the master switch for osteoblast activity. romosozumab is a monoclonal antibody that blocks sclerostin. when you block sclerostin the Wnt pathway goes uninhibited and osteoblasts activate aggressively. but unlike PTH analogs, romosozumab also REDUCES osteoclast activity simultaneously. dual mechanism - formation up, resorption down. only drug that does both at the same time.
the data is honestly absurd compared to everything else:
phase 2 NEJM 2014 (McClung et al): +11.3% lumbar spine BMD in just 12 months at 210mg monthly dose. for reference bisphosphonates take 3-5 years to achieve similar numbers.
damm et al JBMR plus 2025 - vertebral cortical thickness: +53% romosozumab vs +20% teriparatide vs +3% placebo. endocortical thickness: +137.6% romo vs +47.5% teriparatide. cortical BMD: +2.1% romo vs literally -0.1% for teriparatide. cortical mass surface density: +12.4% romo vs +3.8% teri. all statistically significant. romosozumab beat teriparatide on every single cortical measure.
trabecular gains were similar between romo and teri at around 18-22% which tells you the advantage is specifically in cortical bone - exactly the compartment that matters for structural strength.
the FRAME study showed 73% reduction in vertebral fractures vs placebo.
now why isnt this the dimorphism answer? because romosozumab builds bone on ALL surfaces - endocortical, periosteal, trabecular - without sexual specificity. its not driving male-pattern periosteal widening. its building bone everywhere equally. thats amazing for osteoporosis and structural strength but it doesnt make your jaw wider in a sexually dimorphic way. it just makes all your bones thicker and denser.
limitations: FDA approved only for postmenopausal osteoporosis. 12 months maximum treatment duration because the bone formation effect wanes (sclerostin modeling window). cardiovascular safety concern - the ARCH trial showed increased MI and stroke risk vs alendronate. needs follow-up with antiresorptive therapy or you lose the gains.
for length: nothing. for mass: unmatched, best compound that exists. for density: unmatched. for dimorphism: mild - it does increase periosteal apposition but not in a sex-specific pattern.
(McClung et al NEJM 2014; Damm et al JBMR Plus 2025; Poole et al JBMR 2021; FRAME and ARCH trials)
7. BMP-2 and BMP-7 (Bone Morphogenetic Proteins)
these are growth factors in the TGF-b superfamily that directly induce new bone formation from mesenchymal stem cells. they are the most potent osteoinductive molecules known.
the important distinction between the two:
BMP-2 (marketed as rhBMP-2 / INFUSE by medtronic): strongest osteoinduction in vivo of any BMP family member. upregulates Runx2 and osteopontin expression which are the master transcription factors for osteoblast differentiation. this one makes BONE. FDA approved for anterior lumbar interbody fusion and open tibial fractures.
BMP-7 (marketed as OP-1): actually leans more chondrogenic than osteogenic. knippenberg et al (BBRC 2006) showed that BMP-2 stimulated runx2 and osteopontin expression in stem cells within 4 days while BMP-7 stimulated aggrecan (a cartilage marker) at day 14 and actually downregulated the osteogenic genes. BMP-7 makes CARTILAGE more than bone.
the BMP-2/7 heterodimer combination is more potent than either homodimer alone in rodent models (wang et al 2012 - dramatically enhanced new bone formation in rat femoral defects). however this didnt fully translate to human cells - the heterodimer was not a stronger inducer in human adipose stem cells compared to BMP-2 alone (tandfonline 2018).
now the reality check: these are LOCAL implant treatments. they get loaded onto collagen sponges or scaffolds and placed directly at bone defect sites during surgery. they are not systemic drugs. you cannot inject BMP-2 systemically because it would cause ectopic bone formation - meaning bone growing where its not supposed to, plus osteolysis, bone cysts, and severe inflammatory complications. the side effects are dose-dependent and already problematic at FDA-approved doses.
for length: nothing systemically. for mass: extremely powerful but only locally at implant site. for density: powerful locally. for dimorphism: absolutely nothing. these are surgical bone engineering tools not body recomposition compounds.
(Wang et al PMC3388521 2012; Knippenberg et al BBRC 2006; FDA prescribing info for INFUSE and OP-1)
THE ACTUAL SUMMARY
for LENGTH: GH + aromatase inhibitor during mid-late puberty with confirmed open plates. FGFR3 inhibitors only if you have achondroplasia. literally nothing works for length in adults with fused plates. if your plates are closed its over for longitudinal growth and no compound changes this.
for MASS: romosozumab demolishes everything else. +11% spine BMD in 12 months, +53% cortical thickness. then PTH analogs in second place. then androgens. then GH in a distant fourth.
for DENSITY: same ranking. romosozumab then PTH then androgens. aromatase inhibitors actually hurt density.
for DIMORPHISM: androgens are the only drug class that specifically drives sexually dimorphic periosteal remodeling through AR activation. halotestin at 19x AR potency is the theoretical maximum. trenbolone at 3-5x is a distant second. romosozumab builds bone everywhere but not in a dimorphic pattern. GH builds size not shape. everything else is irrelevant for this category.
the “theoretical optimal stack” during puberty would be GH for length + testosterone for dimorphism + letrozole to delay plate closure. in adulthood the only meaningful interventions are androgens for dimorphism and romosozumab for mass/density. but half of this would wreck your liver, cardiovascular system, and endocrine axis.
This is not medical advice. dont take halotestin. And please dont inject BMP-2 into your mandible. dont run letrozole without bloodwork.
@til<3D
firstly I’m differentiating between 4 categories because most of you mix them up constantly and its painful to see:
- BONE LENGTH = longitudinal growth via epiphyseal plates
- BONE MASS = total amount of bone tissue you have
- BONE DENSITY = mineral content per unit volume (what a DEXA scan measures)
- BONE DIMORPHISM = sexually dimorphic shape - wider jaw, brow ridge, broader frame - driven by periosteal apposition
these are NOT the same thing. a compound can max out one category and do literally nothing for another. if you dont understand this distinction the rest of the thread is useless to you.
1. HGH / GH-IGF-1 AXIS
the most overhyped compound in this community for bone purposes.
GH works through IGF-1 on growth plate chondrocytes. its the primary driver of longitudinal bone growth - this is not debatable, its established endocrinology. GH-deficient mice have 10-15% less pubertal bone expansion than wild type. in children with GH deficiency, recombinant HGH is the standard treatment and it works.
BUT - and this is where most of you are coping - GH/IGF-1 does NOT create sexual dimorphism. callewaert et al (JBMR 2010) showed that IGF-1 knockout mice have literally zero skeletal sexual dimorphism. the bones are smaller but equally shaped between sexes. GH makes bones bigger in all directions. it does not make them more male. these are completely different processes mediated by completely different receptors.
for length its probably the best single compound if your plates are open. for mass and density its moderate at best. for dimorphism its basically irrelevant.
length: very strong. mass: decent. density: mediocre. dimorphism: basically nothing.
requirement: open growth plates for any length effect. adults only get mild mass/density benefits and even those are debatable at non-supraphysiological doses.
(Callewaert et al 2010; Venken et al JBMR 2005; Vanderschueren Endocr Rev 2004)
2. ANDROGENS (Testosterone, DHT, Trenbolone)
this is where dimorphism actually is superior. if you care about sexually dimorphic bone structure - wider mandible, more prominent brow, thicker zygomatic arches, broader clavicles - androgens via the androgen receptor are the primary and arguably only proven mechanism.
the pathway: AR activation on periosteal osteoblasts -> new bone laid on the OUTER surface of existing bone -> increased cortical thickness, greater cross-sectional area, more bending resistance. vandenput and ohlsson (PMC3955330, 2014) confirmed that androgens promote trabecular bone thickness in young adulthood and cortical consolidation through periosteal apposition in midlife and beyond. male periosteal bone formation runs about 70% higher than female during puberty. this is what makes male skulls and frames look male.
now the potency ranking for dimorphism specifically:
halotestin (fluoxymesterone) - 19x AR potency vs testosterone. does not aromatize (c11b hydroxyl blocks aromatase). no progestogenic activity. uniquely inhibits 11b-HSD2 which blocks cortisol inactivation in bone tissue (odermatt et al toxicol sci 2012, PMID 22273746). estimated dimorphic remodeling potency roughly 8-10x testosterone.
trenbolone - 3-5x AR potency vs testosterone. does not aromatize. BUT it IS progestogenic which suppresses endogenous testosterone and estrogen production over time. you actually need some estrogen for bone mineralization so tren can impair this long term. estimated roughly 3-4x testosterone for dimorphism.
DHT - about 3x AR potency vs testosterone. does not aromatize. however it gets metabolized by 3a-HSD in bone tissue which reduces local potency. roughly 3x testosterone in theory but probably less in practice.
testosterone - the baseline at 1x. aromatizes to estrogen which simultaneously helps density but also narrows the medullary cavity via endosteal apposition. mixed bag for pure dimorphism.
nandrolone - 1-2x AR, slightly aromatizes, progestogenic. roughly similar to test, maybe slightly worse for dimorphism because of the progesterone activity.
androgens overall: moderate for length (only during puberty), decent for mass, decent for density, unmatched for dimorphism.
(Saartok et al J Steroid Biochem 1984; Vandenput & Ohlsson PMC3955330 2014; Vanderschueren JCEM 2006)
3. FGFR3 INHIBITORS / CNP ANALOGS (Vosoritide, Infigratinib, TYRA-300)
FGFR3 is a receptor that when overactivated acts as a BRAKE on endochondral bone growth. its gain-of-function mutations cause achondroplasia (dwarfism). these drugs release that brake.
vosoritide is a CNP analog - it binds NPR-B receptor which inhibits the MAPK pathway downstream of FGFR3. infigratinib and TYRA-300 are direct FGFR3 tyrosine kinase inhibitors that block the receptor itself.
the clinical data: vosoritide phase 3 RCT showed +1.57 cm/year growth velocity vs placebo in achondroplasia kids aged 5-12 (savarirayan et al, lancet). meta-analysis across 696 patients showed +1.82 cm/year. in mouse models TYRA-300 normalized long bone length by 25-26% toward wild type. infigratinib at higher doses showed more bone growth than vosoritide in the same mouse model (JCI insight 2025).
now the critical part most of you will ignore: these were developed for people with pathologically overactive FGFR3. in a normal person FGFR3 is already functioning at baseline levels. inhibiting it in someone without the mutation could cause unpredictable cartilage and bone overgrowth. this is NOT a height supplement for healthy people. we have essentially zero data on what FGFR3 inhibition does to normal human growth plates.
pure length compound. zero effect on mass, density, or dimorphism. requires open growth plates. designed for a specific genetic disease.
(Savarirayan et al Lancet 2020; JCI Insight 2025; BioMarin clinical data)
4. PTH ANALOGS (Teriparatide / Forteo, Abaloparatide / Tymlos)
intermittent PTH pulses directly stimulate osteoblasts. teriparatide is recombinant PTH(1-34). abaloparatide is a PTHrP analog that supposedly causes less bone resorption. both increase bone formation rate on all surfaces - trabecular and cortical.
the data: teriparatide gives you about +20% trabecular vertebral vBMD at 12 months. cortical thickness increased about 4.3% at lumbar vertebrae. P1NP (formation marker) goes through the roof. these are real numbers from real trials.
the catch: PTH also increases bone resorption. its pro-remodeling meaning it speeds up both formation AND breakdown. the net gain is positive but its not as clean as romosozumab which actually suppresses resorption at the same time.
for length: nothing. for mass and density: strong, probably the second best option after romosozumab. for dimorphism: weak because it acts on all bone surfaces equally - endosteal, periosteal, trabecular. it doesnt preferentially drive periosteal apposition in a sexually dimorphic pattern.
(Neer et al NEJM 2001; multiple phase 3 trials)
5. AROMATASE INHIBITORS (Letrozole, Anastrozole, Exemestane)
this is the one that gets the most hype in these communities and also the most misunderstood.
the mechanism is simple: estrogen is the primary signal for growth plate closure. block estrogen production -> plates stay open longer -> more years of longitudinal growth -> taller adult height. men with aromatase gene mutations were still growing past age 24 with unfused plates and ended up over 190cm. the biology is clear.
letrozole is more potent than anastrozole - 88% vs 85% tissue aromatase blockade with residual estradiol at 5.9% vs 10.1% respectively.
the data: wickman et al (lancet 2001) RCT in boys with constitutional delay of puberty - letrozole + testosterone group saw predicted adult height increase of 5.1 cm (p=0.004) vs testosterone + placebo. bone age advanced only 0.9 years in 18 months with letrozole vs 1.7 years with placebo. thats a massive slowdown in skeletal maturation.
hero et al 2006 confirmed near-final height increase with letrozole during adolescence. final height for letrozole group was 171 cm vs 168.8 cm for controls (p=0.04) in one smaller study.
BUT - and this is a big but - varimo et al (frontiers 2019) showed that letrozole given to PRE-pubertal or EARLY pubertal boys did NOT increase adult height at all. 164.8 cm letrozole vs 163.7 cm placebo, not significant. timing matters enormously. it seems to work best during mid to late puberty when growth plates are actively being pushed toward closure by rising estrogen.
the downsides nobody wants to talk about: AIs dont make bones grow faster. they just keep plates open. you also lose estrogen-mediated bone density benefits. some studies found vertebral deformities in AI-treated boys. bone density at the lumbar spine was lower in letrozole-treated boys. estrogen is genuinely important for bone health in males and nuking it has consequences.
for length: strong but only indirectly and only with correct timing during puberty. for mass: bad, probably net negative. for density: actively harmful - estrogen is essential for density. for dimorphism: mild indirect benefit because you get more time with androgens acting on periosteal bone without estrogenic epiphyseal closure, but you also lose estrogen-mediated endosteal apposition.
(Wickman et al Lancet 2001; Hero et al Clin Endocrinol 2006; Varimo et al Front Endocrinol 2019)
6. ROMOSOZUMAB (Evenity - Anti-Sclerostin Antibody)
this is the actual king of bone mass and density and it isnt close.
sclerostin is a protein produced by osteocytes that inhibits the Wnt/b-catenin pathway, which is basically the master switch for osteoblast activity. romosozumab is a monoclonal antibody that blocks sclerostin. when you block sclerostin the Wnt pathway goes uninhibited and osteoblasts activate aggressively. but unlike PTH analogs, romosozumab also REDUCES osteoclast activity simultaneously. dual mechanism - formation up, resorption down. only drug that does both at the same time.
the data is honestly absurd compared to everything else:
phase 2 NEJM 2014 (McClung et al): +11.3% lumbar spine BMD in just 12 months at 210mg monthly dose. for reference bisphosphonates take 3-5 years to achieve similar numbers.
damm et al JBMR plus 2025 - vertebral cortical thickness: +53% romosozumab vs +20% teriparatide vs +3% placebo. endocortical thickness: +137.6% romo vs +47.5% teriparatide. cortical BMD: +2.1% romo vs literally -0.1% for teriparatide. cortical mass surface density: +12.4% romo vs +3.8% teri. all statistically significant. romosozumab beat teriparatide on every single cortical measure.
trabecular gains were similar between romo and teri at around 18-22% which tells you the advantage is specifically in cortical bone - exactly the compartment that matters for structural strength.
the FRAME study showed 73% reduction in vertebral fractures vs placebo.
now why isnt this the dimorphism answer? because romosozumab builds bone on ALL surfaces - endocortical, periosteal, trabecular - without sexual specificity. its not driving male-pattern periosteal widening. its building bone everywhere equally. thats amazing for osteoporosis and structural strength but it doesnt make your jaw wider in a sexually dimorphic way. it just makes all your bones thicker and denser.
limitations: FDA approved only for postmenopausal osteoporosis. 12 months maximum treatment duration because the bone formation effect wanes (sclerostin modeling window). cardiovascular safety concern - the ARCH trial showed increased MI and stroke risk vs alendronate. needs follow-up with antiresorptive therapy or you lose the gains.
for length: nothing. for mass: unmatched, best compound that exists. for density: unmatched. for dimorphism: mild - it does increase periosteal apposition but not in a sex-specific pattern.
(McClung et al NEJM 2014; Damm et al JBMR Plus 2025; Poole et al JBMR 2021; FRAME and ARCH trials)
7. BMP-2 and BMP-7 (Bone Morphogenetic Proteins)
these are growth factors in the TGF-b superfamily that directly induce new bone formation from mesenchymal stem cells. they are the most potent osteoinductive molecules known.
the important distinction between the two:
BMP-2 (marketed as rhBMP-2 / INFUSE by medtronic): strongest osteoinduction in vivo of any BMP family member. upregulates Runx2 and osteopontin expression which are the master transcription factors for osteoblast differentiation. this one makes BONE. FDA approved for anterior lumbar interbody fusion and open tibial fractures.
BMP-7 (marketed as OP-1): actually leans more chondrogenic than osteogenic. knippenberg et al (BBRC 2006) showed that BMP-2 stimulated runx2 and osteopontin expression in stem cells within 4 days while BMP-7 stimulated aggrecan (a cartilage marker) at day 14 and actually downregulated the osteogenic genes. BMP-7 makes CARTILAGE more than bone.
the BMP-2/7 heterodimer combination is more potent than either homodimer alone in rodent models (wang et al 2012 - dramatically enhanced new bone formation in rat femoral defects). however this didnt fully translate to human cells - the heterodimer was not a stronger inducer in human adipose stem cells compared to BMP-2 alone (tandfonline 2018).
now the reality check: these are LOCAL implant treatments. they get loaded onto collagen sponges or scaffolds and placed directly at bone defect sites during surgery. they are not systemic drugs. you cannot inject BMP-2 systemically because it would cause ectopic bone formation - meaning bone growing where its not supposed to, plus osteolysis, bone cysts, and severe inflammatory complications. the side effects are dose-dependent and already problematic at FDA-approved doses.
for length: nothing systemically. for mass: extremely powerful but only locally at implant site. for density: powerful locally. for dimorphism: absolutely nothing. these are surgical bone engineering tools not body recomposition compounds.
(Wang et al PMC3388521 2012; Knippenberg et al BBRC 2006; FDA prescribing info for INFUSE and OP-1)
THE ACTUAL SUMMARY
for LENGTH: GH + aromatase inhibitor during mid-late puberty with confirmed open plates. FGFR3 inhibitors only if you have achondroplasia. literally nothing works for length in adults with fused plates. if your plates are closed its over for longitudinal growth and no compound changes this.
for MASS: romosozumab demolishes everything else. +11% spine BMD in 12 months, +53% cortical thickness. then PTH analogs in second place. then androgens. then GH in a distant fourth.
for DENSITY: same ranking. romosozumab then PTH then androgens. aromatase inhibitors actually hurt density.
for DIMORPHISM: androgens are the only drug class that specifically drives sexually dimorphic periosteal remodeling through AR activation. halotestin at 19x AR potency is the theoretical maximum. trenbolone at 3-5x is a distant second. romosozumab builds bone everywhere but not in a dimorphic pattern. GH builds size not shape. everything else is irrelevant for this category.
the “theoretical optimal stack” during puberty would be GH for length + testosterone for dimorphism + letrozole to delay plate closure. in adulthood the only meaningful interventions are androgens for dimorphism and romosozumab for mass/density. but half of this would wreck your liver, cardiovascular system, and endocrine axis.
This is not medical advice. dont take halotestin. And please dont inject BMP-2 into your mandible. dont run letrozole without bloodwork.
@til<3D
Last edited:
